Belgium-based biotech company 4Tissue has raised €1.5 million in funding to further develop its bioresorbable hydrogel technology, a potential alternative for breast reconstruction and tissue regeneration. The funding consists of €1 million in equity investments from strategic investors and additional grant support. The company plans to allocate the funds toward research, clinical trials, and regulatory preparations. 4Tissue is also expanding its leadership team, appointing Dr. Katleen Verleysen as an independent chair to strengthen its strategic direction.
Earlier developments in tissue reconstruction have mostly relied on traditional methods such as implants or fat grafting, which come with varying levels of complexity and patient outcomes. 4Tissue’s focus on hydrogel technology represents an effort to provide a less invasive alternative. In previous funding rounds, the company secured initial investments that supported the early stages of its research and development. With this latest financial boost, the company is preparing for clinical trials to validate the effectiveness of its approach.
What is 4Tissue developing?
The company’s research revolves around bioresorbable hydrogels, which could serve as a more accessible and efficient solution for breast reconstruction after cancer treatment. Unlike traditional surgical methods, this technology is designed to minimize the need for complex procedures and reduce recovery time. The approach is also being explored for broader applications in tissue regeneration beyond breast reconstruction.
Who is joining the leadership team?
4Tissue announced that Dr. Katleen Verleysen, currently the CEO of miDiagnostics, will take on the role of independent chair of the board. She has previously held leadership positions across biotech firms in both Europe and the U.S., contributing to funding strategies and corporate growth. Dr. Verleysen stated,
“4Tissue is on the verge of revolutionising breast reconstruction after a breast cancer treatment and regenerative medicine, and I am excited to contribute to this transformation. It’s not just a technical breakthrough—it’s a solution that can drastically improve the lives of women recovering from breast cancer, a disease that affects millions worldwide.”
Founded as a spin-off from Ghent University, Ghent University Hospital, and Vrije Universiteit Brussel, 4Tissue was established through the collaboration of experts in reconstructive surgery and polymer chemistry. Professors Phillip Blondeel and Sandra Van Vlierberghe played a pivotal role in developing the company’s core technology. Key figures also include Dr. An Van Den Bulcke, Dr. Lana Van Damme, and Bernard Depypere, who contribute to the company’s research and operational strategies.
The company aims to differentiate itself by offering a less invasive alternative to existing breast reconstruction techniques such as lipofilling. By developing injectable hydrogels, 4Tissue intends to simplify procedures while maintaining effective results. CEO Dr. Benoit Moreaux highlighted the significance of Dr. Verleysen’s appointment, stating,
“Katleen’s deep knowledge and strategic vision within the life sciences sector make her a valuable addition to our board. Her experience in leading companies through successful funding rounds and building strategic partnerships perfectly aligns with our ambitions to redefine the future of breast reconstruction and tissue regeneration.”
As 4Tissue prepares for clinical trials, regulatory approvals will be a key factor in determining the speed at which the technology can reach patients. The company’s focus on securing regulatory expertise and quality control measures indicates an effort to meet industry standards and gain market acceptance. If successful, the hydrogel technology could present a new option for individuals seeking alternatives to conventional reconstructive surgery.
The effectiveness of bioresorbable hydrogels in clinical applications remains to be fully validated through trials. While the technology promises a new approach to tissue reconstruction, its real-world impact will depend on trial results and regulatory clearance. If proven successful, it could offer a new solution for breast cancer patients undergoing reconstruction. Investors and industry professionals will be closely observing 4Tissue’s progress in the coming years.
